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ABSTRACT
SLM2 and Sam68 are splicing regulator paralogs
that usually overlap in function, yet only SLM2 and
not Sam68 controls the Neurexin2 AS4 exon impor-
tant for brain function. Herein we find that SLM2
and Sam68 similarly bind to Neurexin2 pre-mRNA,
both within the mouse cortex and in vitro. Pro-
tein domain-swap experiments identify a region in-
cluding the STAR domain that differentiates SLM2
and Sam68 activity in splicing target selection, and
confirm that this is not established via the variant
amino acids involved in RNA contact. However, far
fewer SLM2 and Sam68 RNA binding sites flank the
Neurexin2 AS4 exon, compared with those flanking
the Neurexin1 and Neurexin3 AS4 exons under joint
control by both Sam68 and SLM2. Doubling binding
site numbers switched paralog sensitivity, by plac-
ing the Neurexin2 AS4 exon under joint splicing con-
trol by both Sam68 and SLM2. Our data support a
model where the density of shared RNA binding sites
around a target exon, rather than different paralog-
specific protein–RNA binding sites, controls func-
tional target specificity between SLM2 and Sam68
on the Neurexin2 AS4 exon. Similar models might
explain differential control by other splicing regula-
tors within families of paralogs with indistinguish-
able RNA binding sites.
INTRODUCTION
Around 95% of human genes encode multiple mRNA iso-
forms with different exon contents, thus greatly expanding
the informational capacity of the genome. RNA binding
proteins play a key role in creating different mRNA splice
isoforms, by binding to target sites within pre-mRNAs and
directing splice site choice by the spliceosome. These RNA–
protein binding sites contribute to a splicing code through
which the exon–intron structure of pre-mRNAs is deci-
phered (1–3). This splicing code includes RNAbinding sites
for proteins that activate and repress exon inclusion, called
splicing enhancer and repressor sequences respectively, as
well as the splice sites that they regulate. RNA binding sites
can be both exon-proximal and sometimes deep intronic (4).
In vertebrates, many splicing regulator proteins belong to
families of evolutionarily related, similar sister proteins that
often, but not always, regulate the same target exons. These
sister proteins include the STAR proteins SLM2, Sam68
and SLM1; the Transformer proteins Tra2 and Tra2; the
Polypyrimidine Tract Binding Proteins PTBP1-3; the Mus-
cleblind proteins MBNL1–3; the Epithelial Specific RNA
Splicing regulator proteins ESRP1 and ESRP2; RNA bind-
ing Fox1 homolog proteins RBFOX1–3; TIAL and TIA1;
as well as others (5). Many of these paralogs were cre-
ated by gene duplications very early in vertebrate evolution.
However, to what extent very similar splicing regulator par-
alogsmight select overlapping versus distinct targets is often
poorly understood, as are why such similar paralogs have
been maintained often over considerable periods of evolu-
tionary time.
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An important example of differential splicing regula-
tor paralog function is found within the nervous system.
Here, the STAR family RNA binding proteins Sam68 (also
known as KHDRBS1), SLM1 (also known as KHDRBS2)
and SLM2 (also known asKHDRBS3 and T-STAR) differ-
entially regulate splicing patterns of the Neurexin1–3 genes
involved in brain function (6–9). The Neurexin1–3 genes
encode trans-membrane pre-synaptic proteins, mutations
in which are associated with various conditions including
schizophrenia and autism (10), indicating the crucial role
played by their regulation for proper brain functions. Each
Neurexin gene has several alternative exons called alterna-
tive segments 1–5 (abbreviated AS1–AS5), and through al-
ternative splicing of these exons can produce many differ-
ent mRNA isoforms (11). While SLM2 and Sam68 usu-
ally function interchangeably in splicing regulation within
transfected cells and both repress inclusion of theNeurexin1
and Neurexin3 AS4 exons, only SLM2 but not Sam68 reg-
ulates the Neurexin2 AS4 exon (6). These AS4 splicing
patterns are physiologically important, as manipulation of
Neurexin1 and Neurexin3 AS4 alternative splicing affects
both mouse behavior and synapse function (12,13).
SLM2 and Sam68 are 62% identical, and have similar
modular organisations, including a STAR domain com-
prising a KH domain and flanking regions that medi-
ate protein–protein and protein–RNA interactions, an RG
(arginine/glycine)-rich region and C-termini enriched in ty-
rosine residues (14). Based on atomic level resolution from
X-ray crystallography and nuclear magnetic resonance (15),
SLM2 and Sam68 proteins bind RNA via their STAR do-
mains, with largely overlapping but not identical RNA–
protein contacts with the same U(A/U)AA target sequence
(abbreviatedUWAA) (15–17). There is a 51-nucleotide clus-
ter of intronic Sam68/SLM2 binding sites immediately
downstream of the Neurexin2 AS4 exon that mediates the
splicing response to SLM2 (6), but the features underlying
differential regulation of Neurexin2 AS4 splicing by SLM2
and not by Sam68 remain unclear. Herein, we have investi-
gated the features of the SLM2 and Sam68 proteins and of
the target Neurexin2 pre-mRNA that enable this different
splicing activity, and elucidate distinct physiological prop-
erties of these closely related protein paralogs.
MATERIALS AND METHODS
Crosslinking-immunoprecipitation experiment
The CLIP assay was performed as previously described
(18,19). In brief, dissociated cortex tissues were irradiated
on ice (100 mJ/cm2). The cell suspension was centrifuged
at 4000 rpm for 3 min, and the pellet was incubated for 10
min on ice in lysis buffer (50-mM Tris, pH 8.0, 100-mM
NaCl, 1% NP-40, 1-mM MgCl2, 0.1-mM CaCl2, 0.5 mM
Na3VO4, 1-mM DTT, protease inhibitor cocktail [Sigma-
Aldrich] and RNase inhibitor [Promega]). Samples were
briefly sonicated and incubated with DNase (RNase-free;
Ambion) for 10 min at 37◦C and then centrifuged at 15 000
g for 10 min at 4◦C. One milligram of extract was immuno-
precipitated using anti-STAR (Santa Cruz Biotechnology,
Inc.) or IgG (negative control) in the presence of protein G
magnetic (Life Technologies). 1 U RNase I (Ambion) was
added to immunoprecipitates and incubated for 2 h at 4◦C
under rotation. After stringent washes, 10% was kept as a
control to test efficiency of immunoprecipitation by west-
ern blot, while the rest of the immunoprecipitated samples
were treated with 50 g Proteinase K and incubated for 1
h at 55◦C. RNA was then isolated by standard procedures
and retrotranscribed with random primers, using M-MLV
reverse transcriptase (Promega). qPCR was performed us-
ing LightCycler 480 SYBR green I Master and the Light-
Cycler 480 System (Roche) according to the manufacturer’s
instructions. RNA associated with STAR proteins is rep-
resented as fold enrichment relative to IgG samples. All
primers used are listed in Supplementary file 1.
Fluorescence polarization
Sam68 and SLM2 STAR domains were produced as previ-
ously described (15). RNAoligonucleotides were purchased
from Dharmacon, GE Healthcare, deprotected according
to the manufacturer’s instructions, lyophilized, and resus-
pended in ddH2O. All RNAs used for fluorescence polar-
ization contained a fluorescein tag and three cytosines at
the 5′ end of the sequence described in Table 1.
Fluorescence polarization experiments were carried out
in black 96-well plates with a 50 l sample volume per
well in 10 mM Tris pH 7, 100 mM NaCl, 0.1% -
mercaptoethanol. Sam68 and SLM2 domains were serially
diluted across the plate from 200 to 0 M. Fluorescein-
labeledRNAwas then added at 0.2Mfinal concentration.
Plates were analyzed using a Perkin Elmer Victor X5 plate
reader at excitation wavelength of 531 nm and emission at
595 nm, and experiments were carried out in triplicate.
Genomic sequences
Neurexin1–3 sequences were retrieved from NCBI database
(http://www.ncbi.nlm.nih.gov), using the annotation
search tools available in the Geneious 7.1.5 package
(Biomatters, http://www.geneious.com/). Accession num-
bers: Homo sapiens (NG 011878.1; NC 000011.10;
NC 000014.9), Mus musculus (18189; 18190; 18191),
Sarcophilus harrisii (100090577; 100917908; 100928491),
Macropus eugenii (ENSMEUG00000007055; ENS-
MEUG00000016641; ENSMEUG00000001347), Or-
nithorhynchus anatinus (100090577; 100073756), Pelodiscus
siniensis (102449503; 102447445; 102449503), Alligator
mississippiensis (102558540; 102566256; 102570703),
Xenopus tropicalis (100127647), Danio rerio (BX255907;
CR751231; BX571723; NW 001884422).
Minigenes and creation of hybrid proteins
Minigeneswere cloned into pXJ41 using the primers in Sup-
plementary File S1, and mutagenesis was carried out by
overlap PCR as previously described (20). Minigene splic-
ing patterns were analysed in HEK293 cells 24 h after co-
transfection either with GFP, SLM2-GFP or SAM68-GFP
as previously described (6). Tissue culture, transfection of
HEK293 cells, RNA purification and RT-PCR was carried
out using primers and conditions as previously described
(21) and the RT-PCR products were analysed by capillary
gel electrophoresis (20). To enable analysis of splicing pat-
terns as well as monitoring the expression of transfected
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Table 1. Affinity measurements of the STAR domains of T-STAR and SAM68 proteins to target RNAs from Neurexin2 and Stxbp5l carried out using
fluorescence polarization (FP)
SLM2 SAM68
Nrxn2 WT 5.9 ± 0.9 2.9 ± 0.3
Nrxn2 mutant 7 3.9 ± 0.4 3.4 ± 0.3
UAAAAx4 7.9 ± 1.2 6.9 ± 0.8
Stxbp5l 1 24.0 ± 5.9 15.5 ± 4.5
Stxbp5l 2 18.2 ± 3.3 13.8 ± 2.6
Poly(C) >100 >100
Poly(C) was used as a negative control. Affinities are given in Kd (M) with standard deviations derived from three independent experiments. The RNA molecules used for FP
experiments were Nrxn2 WT:
5′-AAUUAAUUAAUUAAUUAACUAACUAACUAACUUUAAAAACACGAUCUUAAA-3′ ;
Nrxn2mutant7:
5′-AAUUAAUUAAUUAAUUAACUAACCCACCCACCCUAAAAACACGAUCUUAAA-3′ ;
UAAAAx4: 5′-UAAAAUAAAAUAAAAUAAAA-3′ ;
Stxbp5l 1: 5′-ACAGUUUAAAAUUUGAUAAAAUUU-3′;
Stxbp5l 2: 5′-UUACAUUUAAAAGAUGAUUUAAAAA-3′.
Poly(C): 5′-CCCCCCCCC-3′.
splicing factors, transfected cell cultures were split into two
portions and analysed by RT-PCR and western blotting as
previously described (22). Splicing patterns were measured
as percentage splicing exclusion (6). All primers used for
splicing assays are provided in the supplementary informa-
tion. Hybrid SLM2 and Sam68 proteins were made by G
block synthesis, and cloned in frame with GFP.
Detection of gene expression in mouse brain tissue
RNA was prepared from brain tissue dissected from wild
type and Khdrbs3 (SLM2) and Khdrbs1 (SAM68) (23)
knockout mice using TRIzol (Life Technologies). The
cDNA was generated using Superscript 3 (Invitrogen) and
analysed by RT-PCR using primer pairs described in the
Supplementary Information.
Statistical analysis
Bar charts were plotted and statistical analyses performed
using Graphpad Prism (Graphpad software).
Western blots
Western blots were carried out as described previously (21).
Proteins were detected by western blotting using antibod-
ies specific for GFP (Clontech 632 381 Living Colors A
v monoclonal antibody); SLM2 (6) SAM68 (Santa Cruz
anti-Sam68 sc-333) and for actin -Actin (Sigma-Aldrich,
A5441,1:2000 dilution).
RESULTS
SLM2 and SAM68 proteins bind indistinguishably to the
Neurexin2 pre-mRNA
The mouse cortex is a brain structure that expresses both
Sam68 and SLM2 but negligible levels of SLM1 (8). To
monitor binding of endogenous SLM2 and Sam68 pro-
teins to theNeurexin2 pre-mRNAs within the mouse cortex
we used CLIP (Cross Linking Immunoprecipitation), with
an antibody that recognizes both Sam68 and SLM2 (anti-
STAR antibody, Figure 1A). To properly discriminate be-
tween the two proteins, CLIP experiments were performed
to detect SLM2 in a Sam68 null mouse background, and to
detect Sam68 in a Slm2 null mouse background.
Western blot analysis showed efficient immunoprecip-
itation of both Sam68 and SLM2 from the mouse cor-
tex (Figure 1A), whereas SLM1 was not detected in either
background (data not shown). Quantitative analysis of the
immunoprecipitates showed efficient SLM2 protein cross-
linking to theNeurexin2 pre-mRNA (Figure 1B; ∼100-fold
enrichment of Neurexin2 precipitation with SLM2 com-
pared with IgG), in line with the strong effect of SLM2 ex-
pression on AS4 splicing in the cortex (Figure 1C). Surpris-
ingly however since Sam68 does not controlNeurexin2AS4
exon skipping within the mouse cortex (Figure 1C), Sam68
protein was also efficiently cross-linked to the Neurexin2
pre-mRNA (Figure 1B;∼100-fold enrichment ofNeurexin2
precipitationwith Sam68 comparedwith IgG). Precisemea-
surements using fluorescence polarization (FP) also showed
that SLM2 and Sam68 have very similar in vitro affinity
for the 51 nucleotide UWAA-rich sequence downstream of
the Neurexin2 AS4 exon (Table 1). Hence, these data indi-
cate that the different splicing activity of SLM2 and Sam68
on Neurexin2 AS4 does not correlate with detectable dif-
ferences in Sam68 and SLM2 protein-binding levels to the
endogenous pre-mRNA.
To test whether similar joint binding also occurred on
another functional SLM2 target in the mouse brain, we
analyzed a 171 nucleotide exon within the Stxbp5l gene,
which is one of the few other known splicing targets of
SLM2 besides the Neurexin1–3 genes (6,13). CLIP also de-
tected binding of both Sam68 and SLM2 to theStxbp5l pre-
mRNA within the mouse cortex, although with around 3-
fold higher levels of Sam68 (Figure 1B). Both Sam68 and
SLM2 proteins bound to Stxbp5l RNA probes in vitro in
FP experiments (Table 1). Analysis of physiological splicing
patterns in the mouse cortex (Figure 1D) and other brain
regions (quantitative data for Stxbp5l splicing patterns in
the cortex and other mouse brain regions are shown in Sup-
plementary Figure S1) showed that splicing of this 171 nu-
cleotide Stxbp5l exon responded to knockout of either Slm2
and Sam68. Hence, Stxbp5l is a joint splicing target for both
SLM2 and Sam68, similar to the Neurexin1 and Neurexin3
AS4 exons, and unlike Neurexin2. Note an additional up-
stream 93 nucleotide exon is annotated in some mRNAs
but not in Refseq, and we could detect some inclusion of
this additional exon in the brain (to give the +93 band) but
splicing of this did not respond to deletion of either Sam68
or Slm2.
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Figure 1. Splicing patterns andRNAprotein interactions of theNeurexin2
and Stxbp5l pre-mRNAs within the mouse cortex. (A) Western blot anal-
ysis of CLIP experiments for SLM2 and SAM68 proteins. Immunoprecip-
itations were carried out using an anti-STAR antibody in wild-type (WT),
SAM68 (Sam68−/−) or SLM2 (Slm2−/−) null mouse cortex, and probed
with an antibody that can detect both SLM2 and Sam68. (B) qPCR anal-
ysis of SLM2 and SAM68 protein binding to the Stxbp5l and Neurexin2
pre-mRNAs assayed by CLIP experiments using an anti-STAR antibody
in Sam68 −/− or Slm2−/− null mouse cortex, respectively. Data shown in
the bar charts are averages from four biological replicates. Error bars show
standard error of the mean. Statistical significance of mRNA enrichment
of STAR antibody with respect to control IgG was addressed using t tests,
and is shown on the bar charts as: **P < 0.01. (C, D) Endpoint RT-PCR
and agarose gel electrophoresis analysis of the endogenous splicing pat-
terns of Neurexin2 AS4 (C) and Stxbp5l genes (D) in WT, Sam68−/− and
Slm2−/- mouse cortex.
The STAR domain of SLM2 establishes substrate specificity
for the Neurexin2 AS4 exon
We carried out a series of experiments to identify the re-
gion of SLM2 protein responsible for its differential splic-
ing activity. SLM2 and Sam68 proteins have similar modu-
lar designs, although Sam68 protein is longer because of an
additional 96 amino acid sequence at its N-terminus (Fig-
ure 2A). We first tested if the presence of this additional 96
amino acid sequence at theN-terminuswas sufficient to pre-
vent skipping of Neurexin2 AS4 being induced by Sam68.
Deletion of these 96 amino acids produced a shorter Sam68
protein (Sam6896) that displayed a similar molecular
weight to SLM2 and was efficiently expressed in HEK293
cells (Figure 2B and C). However, when Sam6896 was co-
expressed with a Neurexin2 minigene, it was unable to in-
duce skipping of the AS4 exon (Figure 2D and E), hence
ruling out these 96 amino acids as a contributory factor to
differential regulation of Neurexin2 AS4 splicing.
To identify the domain in SLM2 that enables skipping of
theNeurexin2AS4 exon, we carried out domain swap exper-
iments, in which we replaced either the tyrosine-rich region
of SLM2 (hybrid protein 1), or both the tyrosine rich re-
gion and RG-rich regions of SLM2 (hybrid protein 2), with
their equivalent regions from Sam68 protein (Figure 2B).
After co-transfection with theNeurexin2minigene (6), both
of these hybrid SLM2 proteins were able to induce skipping
of the AS4 exon as well as wild type SLM2 protein (Figure
2D and E).
The above results indicated that a protein region includ-
ing the SLM2 STAR domain is responsible for establish-
ing differential splicing repression of the Neurexin2 AS4
exon between SLM2 and Sam68. The STAR domain of
SLM2 and Sam68 is highly conserved and provides both
a protein–RNA and protein–protein interaction interface
(15,24). However, three amino acid positions show differ-
ences in RNA–protein contact between SLM2 and Sam68:
these are arginine 180 in Sam68 which is substituted by glu-
tamine in SLM2, isoleucine 184 which is a leucine in SLM2,
and valine 197 which is isoleucine in SLM2 (15). To test if
these variant protein–RNA contacts contribute to differen-
tial splicing regulation of Neurexin2 AS4 via establishing
subtle differences in RNA–protein contact, we constructed
a version of Sam68 (called hybrid 3) in which the three
amino acids were converted to those present in SLM2. Hy-
brid 3 protein was unable to induce skipping of Neurexin2
AS4 in minigene co-transfection experiments, showing that
the amino acids with variant RNA–protein contacts be-
tween Sam68 and SLM2 do not mediate the different splic-
ing activity of these two splicing regulators on theNeurexin2
AS4 exon (Figure 2D and E).
A different intronic distribution of SLM2/SAM68 RNA
binding sites flank the Neurexin2 AS4 compared with both
the Neurexin1 and Neurexin3 AS4 exons
Taken together, the above data suggested that different
protein–RNA binding abilities between SLM2 and Sam68
do not differentiate the splicing specificity of these proteins
on the Neurexin2 pre-mRNA. Thus, we asked if sequence
elements in the Neurexin2 pre-mRNA itself could explain
this differential effect. Since earlier genome comparisons
had only examined intronic binding site patterns within the
first 200 nucleotides downstream of each Neurexin1–3 AS4
exon (6), we further mapped the entire flanking intronic se-
quences upstream and downstream of each AS4 exon for
the presence of Sam68/SLM2 binding sites (Figure 3). The
resulting human and mouse maps showed quite different
distributions of Sam68/SLM2 RNA binding UWAA re-
peats flanking the Neurexin2 AS4 exons, compared to the
equivalent regions in the Neurexin1 and Neurexin3 genes.
A striking feature in SLM2/Sam68 binding site distribu-
tions was their particularly low overall occurrence flanking
the Neurexin2 AS4 exon (with the exception of the 51 nu-
cleotide cluster). In contrast, UWAA repeat sequences were
both more frequent and symmetrically distributed in the
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Figure 2. The STAR domain of SLM2 establishes substrate specificity for the Neurexin2 AS4 exon but not through amino acids involved in RNA–protein
contacts. (A) Modular structures of SAM68 and SLM2 protein, showing the important domains above, and amino acid residue positions below each
protein (1–343 for SLM2, and 1–443 for SAM68). (B) Variant SAM68 and SLM2 proteins used in splicing analyses, with SLM2-derived domains coloured
as in part (A) to distinguish them from their corresponding SAM68-derived domains (in black and white). (C) Western blot showing relative expression of
the different SLM2 and SAM68-GFP fusion proteins relative to actin. (D) Bar chart and (E) example capillary gel electrophoretogram showing levels of
splicing of a Neurexin2 AS4 exon from a co-transfected minigene (6) measured after expression of either a GFP fusion protein (black bars) or GFP only
(green bar). Statistical significances were analysed using Graphpad and are indicated as **** (P < 0.0001), or ns (not significant).
intronic regions flanking the mouse and human Neurexin1
AS4 exons (Figure 3). There were also multiple and evenly
distributed UWAA repeat sequences immediately flanking
the mouse Neurexin3 AS4 exon, although UWAA motifs
were scarcer towards the more distant reaches of the up-
streamNeurexin3 intron.We also observed a high density of
UWAA motifs around the Stxbp5l alternative exon in both
the mouse and human genomes, consistent with regulation
by both SLM2 and Sam68 (Figure 1B) (Supplementary Fig-
ure S2).
These general patterns of SLM2/Sam68 binding sites
flanking theNeurexin2 AS4 exons are conserved across dif-
ferent species’ genomes, and particularly within mammals
(Supplementary Figure S3). Thus within each mammalian
genome sequence examined (humans,mice, Tasmanian dev-
ils, and Tammar wallabies; abbreviated Hs, Mm, Sh and
Me respectively in Supplementary Figure S3), there is a
tight cluster of UWAA binding sites in the intron immedi-
ately downstream of the Neurexin2 AS4 yet relatively few
other exon-proximal binding sites either upstream or down-
stream. Also, within each of these species, the Neurexin1
and Neurexin3 AS4 exons have much more extensive flank-
ing distributions of UWAA repeats (particularly down-
stream repeats in the Neurexin3 gene).
Doubling the number of upstream or downstream
SLM2/SAM68 binding site clusters enables skipping
of the Neurexin2 AS4 exon by both SAM68 and SLM2
We engineered two new versions of theNeurexin2AS4mini-
gene (6) to test whether reduced binding site number is
an important parameter in determining specific splicing re-
pression by SLM2 compared to Sam68 (Figure 4A). Both
these new minigenes were ‘wild type’ in that they contained
the 51 nucleotide cluster of SLM2/Sam68 binding sites in
its normal position immediately downstream of the AS4
exon. However, each newminigene contained an second ad-
ditional copy of this 51 nucleotide cluster, placed either up-
stream or further downstream of the Neurexin2 AS4 exon,
and so recapitulates the distributions of binding sites found
flanking the Neurexin1 and Neurexin3 AS4 exons. These
new minigenes and the original wild type minigene were
transfected into HEK293 cells, and the splicing repressive
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Figure 3. Genomic distribution of UWAA repeats bound by SLM2 and SAM68 proteins in the upstream and downstream introns flanking theNeurexin1–
3 gene AS4 exons. The pattern of UWAA motifs across the entire flanking intron sequences upstream and downstream of the AS4 exon (yellow box) are
shown. SLM2 and SAM68 proteins both bind RNA as dimers to individual UWAA motifs separated by >15 nucleotides. Individual UWAA motifs are
differentiated as purple (UUAA) and blue (UAAA) arrowheads. Abbreviations used are Hs: Homo sapiens; and Mm:Mus musculus.
activity of SLM2 and Sam68weremeasured by the absolute
change in Neurexin2 AS4 percentage splicing exclusion.
Strikingly, the extra 51 nucleotide cluster in both of these
two new Neurexin2 AS4 minigenes enabled efficient AS4
exon skipping by both Sam68 and SLM2 (Figure 4B and
C). Hence, doubling the number of RNA binding sites, in
an arrangement either both upstream and downstream, or
just downstream, of theNeurexin2AS4 exon, is sufficient to
confer responsiveness to Sam68 as well as SLM1. Of these
two new minigenes, the version with the combination of 51
nucleotide binding site clusters located both downstream
and upstream of the Neurexin2 AS4 exon had the strongest
effect on splicing control by Sam68, with no significant dif-
ference between the two STAR proteins (both of which are
expressed at similar levels, Figure 4D) in measured splicing
repression (P = 0.2285).
The endogenous downstream position of the SLM2/Sam68
binding cluster does not enable the differential response of
Neurexin2 AS4 to SLM2
Although insertion of the extra 51 nucleotide element into
the downstream site enabled efficient splicing control by
both SAM68 and SLM2, this arrangement also decreased
the background level of splicing exclusion of the Neurexin2
AS4 exon from ∼40% to ∼20% (Figure 4B and C), with
SLM2 giving a stronger splicing repression than SAM68
(∼20% difference, P = 0.0001). We thus tested if the posi-
tion of the 51 nucleotide SLM2/Sam68-binding site cluster
downstream of the Neurexin2 AS4 exon contributes to dif-
ferential splicing control by SLM2.
We made a new set of minigenes within a background
in which the endogenous 51 nucleotide cluster had al-
ready been mutated to block splicing regulation by SLM2
(this starting minigene is called the complete mutation (6)).
An entire 51 nucleotide SLM2/Sam68 binding site cluster
was inserted at sites 112, 163 and 241 nucleotides down-
stream of the 5′ splice site of the Neurexin2 AS4 alternative
exon (Figure 5A). In each case the 51 nucleotide cluster of
Sam68/SLM2 RNA binding sites enabled splicing repres-
sion by co-transfected SLM2 protein just as well as when
it was in the wild type location immediately downstream of
the regulated exon (Figure 5B).
Next, we tested whether switching the 51 nucleotide re-
sponse element into the upstream flanking intron could
also restore sensitivity to SLM2. In order to avoid possi-
ble insertions into either the branchpoint or the polypyrim-
idine tract that are needed for splicing inclusion of the
Neurexin2 AS4 exon, we selected regions for insertion of
this element 42 nucleotides and 100 nucleotides upstream
of the Neurexin2 AS4 exon (25). Both upstream insertions
had no effect on AS4 splicing inclusion when the minigene
was co-transfected with GFP (Figure 5C), showing that no
essential splicing signals had been destroyed. However, for
both these constructs, co-transfection of SLM2 protein still
strongly promoted Neurexin2 AS4 exon skipping (Figure
5C). But, in each case, splicing repression was only exerted
by SLM2 and not by Sam68, indicating that SLM2 can op-
erate in splicing control from different positions relative to
the regulated exon, and that the original immediately down-
stream position is also not a factor that prevents Sam68-
mediated splicing control of this AS4 exon.
SLM2 can efficiently regulate the Neurexin2 AS4 exon even
when it is further depleted of UWAA STAR protein binding
sites
The above experiments indicate that a difference in bind-
ing site density flanking the regulated exon enables splicing
regulation of the Neurexin2 AS4 exon by SLM2 and not
Sam68. The 51 nucleotide element itself contains a number
of SLM2/Sam68 RNA binding sites. To test how many in-
dividual Sam68/SLM2 binding sites are sufficient to enable
splicing repression of Neurexin2 AS4 by SLM2, we further
dissected the 51 nucleotide sequence within its normal loca-
tion.
The 51 nucleotide cluster of SLM2/Sam68 binding sites
downstream of the Neurexin2 AS4 exon contains three dis-
tinct sequence elements (Figure 6A): four UUAA repeats
(sites 1–4 in Figure 6A); directly followed by three CUAA
repeats (site 7 in Figure 6A); followed by a more extended
AU-rich element (containing UUAAAAA and UUAAA,
which are sites 5 and 6 respectively in Figure 6A). Individ-
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Figure 4. Increasing the density of UWAA repeats makes theNeurexin2AS4 exon respond to SAM68 as well as SLM2. (A) Distribution of UWAA repeats
in the wild typeNeurexin2AS4 minigene, and two engineered versions of this minigene that have an additional cluster placed downstream (intron position
+112) or upstream (intron position -100) relative to the AS4 exon. The position of the Neurexin2 AS4 exon is indicated as a yellow pointed bar within
the wild type minigene and for each mutant. The position of the extra 51 nucleotide SLM2 response sequence in each new construct is shown as a black
bar (or a thinner line where these are absent). The edges of the minigene insert, where they are inserted into the exon trap vector pXJ41 are shown as
green arrowheads. (B) Percentage Splicing Exclusion of theNeurexin2AS4 exon after co-expression of the three minigenes with GFP, a SLM2-GFP fusion
protein, or a SAM68-GFP fusion protein. (C) Representative capillary gel electrophoretograms showing splicing control of the wild type or engineered
versions of the Neurexin2 minigene. (D) Western blot showing expression levels of proteins in (B). On the bar chart, statistical significance was addressed
using t tests. ****P < 0.0001; ***P < 0.001; NS, not significant. Error bars show standard error of the mean.
ual mutation of each of the UUAA repeats led to decreased
splicing repression by SLM2, but in each case splicing re-
pression was still statistically significant compared with the
same minigene co-transfected with GFP (sites 1–4, Figure
6B. In particular mutation of sites 3 and 4 resulted in a rel-
atively modest but still significant PSE change). Similarly,
the Neurexin2 AS4 exon was still repressed by SLM2 af-
ter mutation of the UUAAA sequence (site 6, Figure 6B).
Following each change in the 51 nucleotide element, splic-
ing repression was only via SLM2 protein and not Sam68.
The strongest effects on SLM2-mediated exon skipping was
caused by individual mutation of the UAAAA sequence
(site 5, Figure 6B), after which theNeurexin2AS4 exon was
no longer significantly repressed by SLM2. Individual mu-
tation of the CUAA repeat region (site 7) did not prevent
splicing repression by SLM2, but reduced the overall levels
of splicing exclusion from 52% to 31% (site 7 in Figure 6B)
in cells co-transfected with GFP, suggesting that site 7 may
correspond to a normally strong repressive sequence that
is disrupted by the mutation (or alternatively the mutation
may create an enhancer).
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Figure 5. The SLM2 response element controlling the Neurexin2 AS4 exon can operate from both upstream and further downstream of the target exon.
(A) UUAA and UAAA sequence contents of wild typeNeurexin2AS4 minigene and minigenes that have the binding site cluster moved to various intronic
positions upstream or downstream of the AS4 exon. The minigene insert sequence cloned into the pXJ41 exon trap vector is shown, with nucleotide
numbering from the first to last nucleotide of this inserted sequence. The position of the Neurexin2 AS4 exon is indicated as a yellow pointed bar under
the wild type and each mutant. The position of the 51 nucleotide SLM2 response sequence in each construct is shown as a black bar. (B) Effect of moving
the UWAA cluster downstream of the Neurexin2 AS4 exon within the minigene construct, shown a bar chart. (C) Effect of moving the 51 nucleotide
UWAA cluster upstream of the Neurexin2 AS4 exon on exon skipping, shown as a bar chart (data from three biological replicates). Statistical significance
was addressed using t tests, and is shown on the bar charts as: ***P < 0.001; **P < 0.01; *P < 0.05. Error bars show standard error of the mean. Data
previously shown in earlier panels is shown as white bars.
The strongest effect on exon skipping in the above exper-
iments was thus mutation of the UAAAA sequence (posi-
tion 5 in Figure 6A). FP analysis of a (UAAAA)4 sequence
confirmed that this sequence efficiently binds to the STAR
domains of SLM2 and Sam68 proteins in vitro, with a simi-
lar dissociation constant to the full 51 nucleotideNeurexin2
response element (Table 1). To test if an increased num-
ber of UAAAA sites would be sufficient by itself to en-
able Neurexin2 AS4 splicing control by Sam68 as well as
SLM2, we constructed a minigene that contained four con-
secutive repeats of this sequence, (UAAAA)4, to replace
the endogenous single copy of the 51 nucleotide sequence
(previously removed by the complete mutation). The AS4
exon from this (UAAAA)4 minigene construct was included
within mRNAs at similar levels to the wild type control
when co-transfected with GFP (Figure 6C). Insertion of the
(UAAAA)4 sequence downstream of the AS4 exon enabled
very efficient splicing repression by co-expressed SLM2pro-
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Figure 6. Dissection of the 51 nucleotide SLM2 response element downstream of the Neurexin2 AS4 exon. (A) Sequence repeat composition of the 51
nucleotide cluster of Sam68/SLM2 binding sites downstream of the Neurexin2 AS4 exon (6), with the individual tested sequence elements in mutants 1–7
shown underneath. In each case, the mutated nucleotides are shown in red, and wild type nucleotides are black. (B) Effects on splicing exclusion of the
Neurexin2 AS4 exon, after mutating individual components of this repeat sequence shown as a bar chart. (C) Minigene structure after the endogenous
51 nucleotide SLM2 response element is mutated, and a (UAAAA)4 sequence inserted immediately upstream of this mutated sequence. (D) Bar chart
and (E) example capillary gel electrophoretogram showing splicing response of the Neurexin2 AS4 exon after the 51 nucleotide SLM2 response element is
substituted with a (UAAAA)4 sequence. Data shown in all the bar charts are averages from at least three biological replicates, with splicing levels in cells
transfected with GFP data shaded green and splicing levels in cells transfected with SAM68 and SLM2 shaded black. Statistical significance was addressed
using t tests, and is indicated on the bar chart as ****P< 0.0001; ***P< 0.001; **P< 0.01; *P< 0.05. Error bars show standard error of the mean. Data
previously shown in earlier panels is shown as white bars.
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Figure 7. Binding site density controls differential splicing activity of
SLM2 and Sam68 on the Neurexin2 AS4 exon. This model proposes that
the single binding site cluster downstreamof theNeurexin2AS4 exon binds
both Sam68 and SLM2 proteins, but only SLM2 is proficient to cause AS4
skipping. Duplication of this binding site cluster enables joint regulation
by both SLM2 and Sam68.
tein. In fact, the splicing response of the (UAAAA)4 mini-
gene to SLM2 co-expressionwas stronger than thewild type
minigene (∼18% difference, P = 0.0332). Furthermore, the
addition of these four downstream UAAAA repeats were
sufficient to place theNeurexin2AS4 exon under joint splic-
ing control by Sam68 protein, although this was not as
strong as for SLM2. These experiments confirm that the
UAAAA sequence (position 5 in Figure 6A) is the major
determinant of splicing repression by SLM2 protein, and
that Sam68 requires increased density of this site (in this
case four copies instead of one) to cause exon skipping.
DISCUSSION
Here, we propose differential splicing regulation by SLM2
and Sam68 involves the density of RNA–protein bind-
ing sites that flank target exons within the Neurexin pre-
mRNAs, rather than the actual core binding site sequence
per se. Notably, this is the first study that has examined
the basis of interchangeability between two STAR pro-
tein paralogs in vivo. Our data support a model (Figure
7) where Neurexin2 AS4 has a reduced density of flank-
ing Sam68/SLM2 binding sites that can only support splic-
ing control by SLM2. Three lines of evidence led to this
model. Firstly, CLIP experiments (Figure 1B) monitoring
in vivo binding within the mouse cortex and in vitro RNA
binding assays (Table 1) indicate no apparent differences in
Sam68 and SLM2 protein binding to the Neurexin2 pre-
mRNA, even though only SLM2 protein and not Sam68
can repress splicing of this exon in the mouse brain or in
transfected cells. Secondly, based on the recent atomic-level
characterization of SLM2 and Sam68 RNA–protein con-
tacts (15), changing the three Sam68 amino acid residues
within the STAR domain with different RNA–protein con-
tacts into their equivalent amino acid residues in SLM2
(which should in effect turn Sam68 into SLM2 in terms of
RNA–protein contact) was not sufficient to enable splic-
ing regulation of Neurexin2 AS4 by Sam68 (Figure 2)
(15). Thirdly, genome analysis indicated much fewer in-
tronic Sam68/SLM2 binding sites flank theNeurexin2AS4
exon, compared to Neurexin1 and Neurexin3 which are
under joint control by SAM68 protein as well (Figure
3). Similar patterns of SLM2/Sam68 binding sites flank-
ing the Neurexin1–3 AS4 exons are also conserved across
all mammals, consistent with them being functionally im-
portant (Supplementary Figure S3). Thus, all mammalian
Neurexin2AS4 exons have fewer flanking UWAA repeat se-
quences and these are mainly concentrated within a single
downstream cluster, and in each case are more similar to
each other in UWAA distribution across species than to the
corresponding pattern for theNeurexin1 orNeurexin3 gene
within the same species.
Experimentally confirming a prediction of this model,
duplication of the entire intronic 51 nucleotide element
downstream of the Neurexin 2 AS4 exon was sufficient to
enable joint splicing regulation by Sam68 as well as SLM2
(Figure 4B andC).We predict that a finite amount of SLM2
protein bound to the Neurexin2 pre-mRNA is more profi-
cient in its ability to repress Neurexin2 AS4 splicing than a
finite amount of bound Sam68 protein, and that increased
levels of Sam68 binding enabled by binding cluster duplica-
tion enables joint splicing regulation despite this lower pro-
ficiency. Binding site cluster duplication also made the in-
trons flanking the Neurexin2 AS4 exon more closely resem-
ble those that flank the Neurexin1 and Neurexin3 AS4 ex-
ons, thus explaining at a genomic level why Neurexin1 AS4
and Neurexin3 AS4 exons are under joint Sam68/SLM2
splicing control. Also consistent with this prediction, we ob-
served that Sam68 can modulate alternative splicing of an-
other physiological SLM2 target exon in the Stxbp5l gene
(Figure 1C) that also contains higher densities of flanking
UWAAbinding sites than theNeurexin2AS4 exon (Supple-
mentary Figure S2). Stxbp5l pre-mRNA also bound higher
levels of Sam68 within the mouse cortex, possibly because
of higher endogenous expression levels of Sam68 relative to
SLM2. Previous work has shown Sgce exon 8, which is also
controlled in the mouse brain by Sam68, contains many in-
tronic UAAA sequences both upstream and downstream of
the exon, and Sam68 binding in this case also causes exon
exclusion (26,27).
Interestingly, although SLM2/Sam68 binding site clus-
ters can mediate Neurexin2 AS4 splicing control from both
upstream and downstream intronic positions, the highest
fold splicing switch in response to SLM2 and Sam68 co-
expression was achieved with the binding site cluster dupli-
cated downstream of the AS4 exon. An immediately down-
stream position for this cluster of SLM2/Sam68 binding
sites has also been conserved for the endogenousNeurexin2
AS4 exon within each of the genomes we analysed, al-
though our minigene data also indicate that this single clus-
ter canmediate exclusive SLM2-splicing control from either
upstream or downstream intronic positions. A duplicated
downstream intronic binding site cluster did however give a
tighter pattern of control, with less exon skipping after co-
transfection with GFP. While specific RNA–protein con-
tacts did not detectably contribute to differential splicing
regulation of Neurexin2 AS4 by SLM2 and Sam68, STAR
domains are both RNA and protein interaction interfaces,
mediating their ability to homodimerize and heterodimer-
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ize (15,28). As well as RNA binding, protein dimerisation
is essential for the splicing repressive activity of both SLM2
and Sam68 (15,16). SLM2 and Sam68 heterodimerise, and
co-transfection of Sam68 with SLM2 protein inhibits the
activity of SLM2 in splicing control ofNeurexin2AS4, pre-
sumably through inducing formation of a heterodimer that
is no longer sufficient to mediate skipping of this exon (6).
More generally, many splicing regulator proteins exist
in multi-protein families. Multi-protein families may en-
able individual protein members to have evolved differ-
ent patterns of expression, thus providing a mechanism to
vary local concentrations of splicing regulator proteins like
Sam68 (fairly ubiquitously expressed) and SLM2 (mainly
expressed in the testis and brain). The existence of multi-
protein families could also enable individual protein mem-
bers of each family to specialise in splicing control of dif-
ferent targets by evolving different RNA binding specifici-
ties, although the STAR family members Sam68 and SLM2
have been puzzling in sometimes selecting different func-
tional targets while having indistinguishable RNA binding
sites (15). Our model presented here, that splice site den-
sity within target pre-mRNAs influences splicing responses
to Sam68 and SLM2, might also apply to other families of
splicing factors that have indistinguishable RNA target sites
but that control different subsets of splicing targets.
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